186826-86-8

• 常用中文名：盐酸莫西沙星
• 常用英文名：Moxifloxacin HCl
• CAS号：186826-86-8
• 分子式：C₂₁H₂₅ClFN₃O₄
• 分子量：437.892
• 相关类别： 原料药 人工合成抗感染类药 喹诺酮类药
• 发布时间：2018-02-05 08:00:00
• 更新时间：2026-07-03 10:54:59
• Moxifloxacin盐酸盐是氟喹诺酮类抗生素。
• 致癌、致突变
  虽然有关莫西沙星致癌作用的常规长期研究尚未完成，但该药进行了基因毒性体内和体外试验。此外，在大鼠身上进行了对于人类的致癌作用加速试验(诱发和促进测定)。5株Ames试验中4次为阴性，中国苍鼠卵巢HPRT的突变试验和大鼠原发肝细胞的UDS试验也均为阴性，而其它喹诺酮类TA102的Ames试验为阳性。体外试验显示大剂量(33mg/ml)的其它喹诺酮类药物可致中国苍鼠的V79细胞出现染色体异常，然而，小鼠体内试验核仁测定为阴性结果。此外，体内试验测定其对小鼠的显性致死测定为阴性。总之，体内试验的结果充分反映了其体内的基因毒性。在大鼠的诱导和促进测定中未发现莫西沙星致癌的证据。
  光毒性
  莫西沙星对光稳定且潜在光毒性很低。体外试验和动物试验显示莫西沙星的光毒性较其它喹诺酮类药物小。让小鼠口服一些喹诺酮类药物并同时照射紫外线，显示出可增加紫外线的光致癌作用。
  莫西沙星的光致癌作用的研究尚未进行，在志愿者的Ⅰ期试验中证实莫西沙星的光毒性较小。
  心电图
  高浓度的莫西沙星对延迟调整心脏钾离子流有抑制作用，因此导致QT间期延长。给狗口服大于90mg莫西沙星进行毒理研究，导致血药浓度大于16mg/L，引起QT间期延长，但未发现有心律失常出现。但是累积静脉给药高于50倍人的给药剂量(>300mg)，可导致血药浓度≥200mg/L(高于静脉给药治疗浓度的
  30倍)，并观察到可逆转、非严重的室性心律失常。
  关节毒性
  众所周知，喹诺酮类可以造成未成年试验动物的承重关节软骨的病变。可造成幼年狗的关节毒性的最小口服莫西沙星剂量是推荐最大治疗剂量(400mg/50kg人体重)的4倍，其血药浓度为推荐治疗剂量时血药浓度的2-3倍。
  生殖毒性
  用大鼠、兔和猴子进行的生殖研究表明，莫西沙星可以通过胎盘。对大鼠(os和iv)和猴子(os)的试验表明，给予莫西沙星后没有致畸作用和对生殖力的影响证据。兔静脉给药200mg可观察到骨骼畸形。该研究结果与已知的喹诺酮对骨骼发育的影响一致。血浆药物浓度在治疗浓度范围内，猴子和兔的流产发生率增多。在大鼠身上，当口服剂量为按千克体重计算使血药浓度在人治疗剂量范围内所推荐的最大药物剂量的63倍时，会出现幼鼠体重减少、出生前体重减轻增加、轻度延长孕期和增加一些雌性和雄性大鼠的生殖能力等现象。

名称

• 中文名: 盐酸莫西沙星
• 英文名: moxifloxacin hydrochloride
• 中文别名: 莫西沙星及其中间体; 1-环丙基-6-氟-1,4-二氢-8-甲氧基-7-[(4AS,7AS)-八氢-6H-吡咯[3,4-B]吡啶-6-基]-4-氧代-3-喹啉羧酸盐酸盐; 莫西沙星[盐酸]; 盐酸莫西沙星(莫西沙星盐酸盐 一水合物; Moxifloxacin HCl 10mM * 1mL in DMSO试剂; 氘4-盐酸莫西沙星; 盐酸莫西沙星 Moxifloxacin hydrochloride 186-8; 盐酸莫西沙星(含手性侧链); 盐酸莫西沙星 其他抗感染类; 莫西沙星HCL; 盐酸莫西沙星/A1A; 莫西沙星盐酸盐,10 MM DMSO 溶液; 莫西沙星盐酸盐溶液,100PPM; 莫西沙星盐酸盐; 盐酸莫他沙星; 盐酸莫西沙星 标准品; 1-环丙基-7-(S,S-2,8-重氮-二环[4.3.0]壬烷-8-基)-6-氟-8-甲氧-1,4-二氢-4-氧-3-喹啉羧酸盐酸盐; 莫西沙星盐酸盐溶液, 1000PPM; 1-环丙基-7-{S,S-2,8-重氮-二环[4.3.0]壬-8-基}-6-氟-8-甲氧-1,4-二氢-4-氧-3-喹啉羧酸盐酸盐; 莫西沙星盐酸盐/1-环丙基-7-(S,S-2,8-二氮杂双环[4.3.0]壬烷-8-基)-6-氟-8-甲氧-4-氧代-1,4-二氢-3-喹啉羧酸盐酸; 莫西沙星盐酸盐溶液, 1000ΜG/ML; MOXIFLOXACINHYDROCHLORIDE莫西沙星盐酸盐; 莫西沙星(盐酸莫西沙星)检测标准品; 1-环丙基-6-氟-7-((4AS,7AS)-六氢-1H-吡咯并[3,4-B]吡啶-(2H)-基)-8-甲氧基-4-氧代-1,4 -二氢喹啉-3-羧酸盐酸盐; 盐酸莫西沙星(标准品); 盐酸莫西沙星杂质ABCDEFGHJKL; 盐酸莫西沙星"龙胆苦甙
• 英文别名: 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridine-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride; Moxifloxacin (BAY9) HCl; Moxifioxacin hydrochloride; 3-Quinolinecboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, Monohydrochloride, (4aS-cis); 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecboxylic AcidMonohydrochloride; Moxifloxacin; 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride (1:1); Moxifloxacin hydrochloride Solution, 1000ppm; Moxiflaxacin HCL; Moxifloxacin Hydrochloride (200 mg); Moxifloxacin and intermediates; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecboxylic acid hydrochloride (1:1); 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; acide 1-cyclopropyl-6-fluoro-8-méthoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique chlorhydrate; Moxifloxacin：Moxifloxacin HCl; 3-Quinolinecboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7- [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,monohydrochloride; 4-dihydroquinoline-3-cboxylic acid hydrochloride; Moxifloxacin hydrochloride, (HPLC); MoxifL; BAY9 HCl; Nafenac (CAS 78-8) and Moxifloxacin hydrochloride; Moxifloxacin Hyderochlodire; Moxifloxacin D4 HydrochlorideQ: What is Moxifloxacin D4 Hydrochloride Q: What is the CAS Number of Moxifloxacin D4 Hydrochloride Q: What is the storage condition of Moxifloxacin D4 Hydrochloride; Actura; 1-cyclopropyl-7-(S,S)-2,8-diazabicyclo(4.3.0)-non-8-yl-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid hydrochloride; Moxifloxacin hydrochloride solution in Methanol, 1000μg/mL; 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; MOXIFLOXACIN HCL; 1-Cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydro-1H-pyrrolo[3,4-b]pyridin-6(2H)-yl)-8-Methoxy-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride; moxifloxacin for peak identification(Y0000717)Q: What is moxifloxacin for peak identification(Y0000717) Q: What is the CAS Number of moxifloxacin for peak identification(Y0000717); Moxiflocacin hydrochloride; Moxifloxacin hydrochloride CRS; 1-Cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid Hydrochloride; C15338000 Moxifloxacin hydrochloride; AVELOX; AVALOX; Moxifloxacin HCl 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H- pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3- cboxylic acid hydrochloride; Actira; Moxifloxacin HCl (BAY9); (1's,6's)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride; 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid hydrochloride (1:1); 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo-[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride; 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO- 8-METHOXY-7- [(4AS,7AS)-OCTAHYDRO-6H-PYRROLO[3,4-B]PYRIDIN-6-YL]-4-OXO-3-QUINOLINECBOXYLIC ACID HYDROCHLORIDE; Moxifloxacin (Hydrochloride); Moxifloxacin Hydrochloride 1; Moxifloxacin HydrochlorideQ: What is Moxifloxacin Hydrochloride Q: What is the CAS Number of Moxifloxacin Hydrochloride Q: What is the storage condition of Moxifloxacin Hydrochloride; Avelox; 1-Cyclopropyl-6-fluoro-8-Methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride; Avalox; oxacin hydrochL; Moxifloxacin hydrochloride //BP; ACTIRA; BAY-12-8039; Moxifloxacinehydrochloride; 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride; 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-cboxylic acid hydrochloride; AVALOX; 2,4-Imidazolidinedione,5-(3-bromophenyl)-11-methyl; Moxifloxacin Hydrochloride Tablets; Avelox,Avalox; Vigamox; Moxifloxacin Hydrochloride IP/BP; Moxifloxacin Hydrochlorideand; Moxifloxacin hydrochloride hcl; Moxifloxacin hydrochloride, >=; Moxifloxacin HCl (Monohydrate); Moxifloxacin hydrochloride, 10 mM in DMSO; MoxifloxacineHCl; Octegra; 1-Cyclopropyl-6-fluor-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydrochinolin-3-carbonsäurehydrochlorid; MOXIFLOXACIN HYDROCHLORIDE; 7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6- yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-di hydroquinoline-3-cboxylic acid hydrochloride; PROFLOX; Izilox; 1-CYCLOPROPYL-7-[(S,S)-2,8-DIAZA-BICYCLO[4.3.0]NON-8-YL]-6-FLUORO-8-METHOXY-1,4-DIHYDRO-4-OXO-3-QUINOLINE CBOXYLIC ACID HYDROCHLORIDE; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (1:1); MFCD00949117; Moxifloxacin Hcl MH; Moxifloxacin hydrochloride; (1'S,6'S)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-(1,4-dihydroquinoline)-3-carboxylic acid hydrochloride salt; Proflox; Moxifloxacin hydrochlorid; Moxifloxacin Hydrochloride ABCDEFGHJKL

物化性质

• 沸点: 636.4ºC at 760 mmHg
• 分子式: C₂₁H₂₅ClFN₃O₄
• 分子量: 437.892
• 闪点: 338.7ºC
• 精确质量: 437.151764
• PSA: 83.80000
• LogP: 3.56630
• 外观性状: 灰白色到黄色 粉末
• 蒸汽压: 4.56E-17mmHg at 25°C
• 储存条件: 2-8°C

生物活性

• 描述: Moxifloxacin盐酸盐是氟喹诺酮类抗生素。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  研究领域 >> 感染
• 参考文献:

  [1]. Balfour, J.A. and H.M. Lamb, Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs, 2000. 59(1): p. 115-39.

  [2]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.

  [3]. Ioannidis, O., et al., Effect of moxifloxacin on the survival, lipid peroxidation and inflammation of immunosuppressed rats with soft tissue infection from Stenotrophomonas maltophilia. Microbiol Immunol, 2013.

安全

• 危害码 (欧洲): Xi
• 危险品运输编码: NONH for all modes of transport
• RTECS号: VB1983750
• 海关编码: 2933499090

合成路线

151096-09-2 ~74% 186826-86-8

文献：CIPLA LIMITED; CURTIS, Philip, Anthony Patent: WO2008/59223 A2, 2008 ; Location in patent: Page/Page column 15-16 ;

139693-52-0 151213-40-0 ~% 186826-86-8

文献：WO2010/52726 A1, ; Page/Page column 5; 6 ;

496919-99-4 151213-40-0 ~73% 186826-86-8

文献：CIPLA LIMITED; CURTIS, Philip, Anthony Patent: WO2008/59223 A2, 2008 ; Location in patent: Page/Page column 13-14 ;

192927-63-2 ~% 186826-86-8

文献：WO2007/10555 A2, ; Page/Page column 15 ;

112811-72-0 ~% 186826-86-8

文献：EP2551268 A1, ;

151213-40-0 ~% 186826-86-8

文献：EP2551268 A1, ;

112811-70-8 ~% 186826-86-8

文献：Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, , vol. 121, p. 254 - 258

151213-39-7 ~% 186826-86-8

文献：Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, , vol. 121, p. 254 - 258

112811-72-0 151213-40-0 ~% 186826-86-8

文献：Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, , vol. 121, p. 254 - 258

上下游产品

上游产品  7
151096-09-2 139693-52-0 151213-40-0 192927-63-2
112811-72-0 112811-70-8 151213-39-7
下游产品  1
151096-09-2

海关

海关编码	2933990090
中文概述	2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%